STOCKWATCH: J&J points to medtech dip, Novartis lobs MS grenade to Teva
This article was originally published in Scrip
Executive Summary
Second-quarter earnings season kicked off properly this week with the world's largest healthcare company, Johnson & Johnson, reporting (scripintelligence.com, 16 July 2013). The healthcare conglomerate commonly known as J&J has a market capitalisation of nearly $260bn and is so diverse that it provides a window into other pure-play pharmaceutical, consumer, medical device and diagnostic companies, as well as a number of specific drugs, the revenues on which, much smaller companies are dependent.
You may also be interested in...
Stockwatch: Earnings Season Appears Not At Home To Brexit
On the morning of the vote by the UK to leave the EU, I speculated firstly that the ensuing currency swings would come too late to impact the imminent second-quarter pharma earnings announcements but secondly, that they could have an effect on the guidance of companies for the rest of the year. In the opening week of earnings season I am currently one for two in the prediction stakes as the effects of Brexit barely figured in either the results or the full-year guidance.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.